Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00878969 · ClinicalTrials.gov registry record · Phase 3
Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3
A Phase 3 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 78
- Enrollment target
NCT00878969: Clinical Trial Phase 3 study, sponsored by Vanderbilt University.
NCT00878969 is a Phase 3 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 78 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00878969, a Phase 3 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 78 participants
- Enrollment target
Study Summary
The purpose of the study is to see how two classes of blood pressure medications,angiotensin-converting enzyme inhibitors (Ace inhibitors) and angiotensin receptor blockers (ARBs), differ in their long term effects on certain chemicals in the body and on the carotid arteries.
Primary Outcome
IL-6 is a sensitive laboratory assay for serum levels of interleukin-6, which is a pro-inflammatory cytokine used to evaluate the inflammatory response.
Interventions
- DRUG Placebo
- DRUG valsartan (ARB)
- DRUG ramipril (ACE inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2010-01 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
Why NCT00878969 stopped before completion
NCT00878969 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00878969 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00878969 about?
NCT00878969 is a clinical study titled "Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3". The purpose of the study is to see how two classes of blood pressure medications,angiotensin-converting enzyme inhibitors (Ace inhibitors) and angiotensin receptor blockers (ARBs), differ in their long term effects on certain chemicals in the body and on the carotid arteries.
What is the current status of trial NCT00878969?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2010-01. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00878969?
The interventions under investigation include: Placebo (DRUG), valsartan (ARB) (DRUG), ramipril (ACE inhibitor) (DRUG).
Who is sponsoring clinical trial NCT00878969?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00878969's enrollment target sits among peer trials
78 1769th of 2000 higher than 230 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia